博濟醫藥(300404.SZ):全資子公司取得一項發明專利證書
格隆匯10月8日丨博濟醫藥(300404.SZ)公佈,近日,公司全資子公司廣州博濟新藥臨牀研究中心有限公司獲得國家知識產權局頒發的一項發明專利證書,發明名稱為一種治療關節痛的中藥組合物、製劑及製備方法和應用。
本發明屬於中藥製劑領域,本發明通過不同工藝樣品抗炎鎮痛小鼠模型效應評估試驗,發現各工藝樣品,均具一定鎮痛、抗炎作用,可於用關節疼痛、肩周炎、腰椎經盤突出引起的疼痛。本發明處方不僅提高了抗炎藥效,且減去了毒性藥味,安全性更高,藥效更好,並避免了毒性藥味資源匱乏問題。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.